2024
Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial
Blasiak A, Tan L, Chong L, Tadeo X, Truong A, Senthil Kumar K, Sapanel Y, Poon M, Sundar R, de Mel S, Ho D. Personalized dose selection for the first Waldenström macroglobulinemia patient on the PRECISE CURATE.AI trial. Npj Digital Medicine 2024, 7: 223. PMID: 39191913, PMCID: PMC11350179, DOI: 10.1038/s41746-024-01195-5.Peer-Reviewed Original ResearchArtificial intelligenceClinical decision support systemsDecision support systemIntegration of AIAI-enabled toolsWaldenstrom's macroglobulinemiaBruton tyrosine kinase inhibitor ibrutinibRare diseaseEnhance usersWaldenstrom's macroglobulinemia patientsKinase inhibitor ibrutinibSupport systemSecondary outcome measuresDiagnosed WMDigital health solutionsWM patientsInhibitor ibrutinibMacroglobulinemia patientsDosing recommendationsUsersManagement of rare diseasesClinical efficacyDevelopment of digital technologiesDose selectionPersonalized therapy
2022
PRECISE CURATE.AI: A prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence.
Blasiak A, Truong A, Jeit L, Kumar K, Tan S, Teo C, Tan B, Tadeo X, Tan L, Chee C, Yong W, Ho D, Sundar R. PRECISE CURATE.AI: A prospective feasibility trial to dynamically modulate personalized chemotherapy dose with artificial intelligence. Journal Of Clinical Oncology 2022, 40: 1574-1574. DOI: 10.1200/jco.2022.40.16_suppl.1574.Peer-Reviewed Original ResearchStandard-of-careSingle-agent capecitabineCapecitabine doseProspective feasibility trialClinical trialsChemotherapy doseSolid tumorsImprove patient response ratesDosing decisionsTreatment of solid tumorsIndividualize chemotherapy dosingAdvanced solid tumorsProspective clinical trialPatient response rateRandomized clinical trialsPrescribed dosePatient-specific variationsOpen-labelDosing recommendationsTumor markersOrgan dysfunctionPatient comorbiditiesDose selectionOncological indicationsCapecitabine